(Total Views: 678)
Posted On: 06/17/2024 2:43:35 PM
Post# of 148870
Leronlimab Regulator List (a work in progress)
[+] = upregulation
[-] = downregulation
a-SMA [-]
a1-antitrypsin [+]
ADA2 (CCL5 migration to site of injury) [-]
AKT (via blockade of CCL4)[-], AMPK [+]
arachidonic acid (upregulated by CCL2, CCL3, CCL4, CCL5, CCL7 [-]
CCL8)[-]
AP-1 [-]
ARG1 [-]
ASC proteins (via NLRP3 downreg)[-]
ATP (via CCL5 downreg) [-]
b-arrestin [-]
BACH2 (via decrease of inflammatory TREG reaponse) [+]
Bcl-2 [-]
BDNF [+]
bradykinin[-]
beta- catenin (via downreg CCL5/CCL2) [-]
bFGF (-)
BTK (via SYK) [-]
c-Raf (via downreg of b-arrestin) [-]
caspase-1 (via NLRP3/ASC downreg) [-]
capase-3 [-]
capase 9 [-]
C5a [-]
CA-2+[-]
Calcineurin (via downreg CA-2+[-]
cAMP (via CD38)[-]
CCL2 (MCP-1)[-]
CCL3 (MIP-1a)[-]
CCL4 (MIP-1b)[-]
CCL5 (RANTES)[-]
CCL7 (MCP-3)[-]
CCL8 (MCP-2)[-]
CCL11(Eotaxin-1)(low binding affinity) (high binding of CCR3)[-]
CCL13 (MCP-4)[-]
CCL14 (HCC-1)[-]
CCL16 (HCC-4)[-]
CCL18 [-]
CCL20 (LARC MIP3A)(not a CCR5 ligand) (via NF-kB downreg)[-]
CCR1 (via TNF-a and IL-4) [-]
CD25 (aka p55)(IL-2 receptor) [-]
CD69 [+]
CDK2 (via CCL5 downreg) [-]
CDK4 (via CCL5 downreg) [-]
CDK6 (via CCL5 downreg) [-]
CREB [+]
CTLA-4 (via IFN-a downreg)[-]
CX3CL1 (fractalkine) (NF-kB /TNF-a downregulation)[-]
CXCL1 [-]
CXCL8 [-]
CXCR4 (via downreg IL-17a, cyclin D1 (via CCL5 downreg) [-]
cyclin E (via CCL5 downreg) [-]
cytochrome c (via CCL5 downreg)[-]
DNMT1 (vis downreg of STAT3)[-]
ECM [-]
EGF/EGFR (in cancer via downreg fibroblasts, downreg GRP78) [-]
EGR-1 (via downreg of MAPK)[-]
eIF2a (via PKR downreg) [-]
eIF4E [-]
EN-RAGE [-]
Erk 1 and 2[-]
FAK (via CCL5) [-]
FLNa, FOXP3 (downregulation of PKB/Akt pathway)[+]
GLP-1 [+]
GLUT-1 (via CCL5 downreg) [-]
GM-CSF (CSF2)[-]
GPR75 (increased binding of CCL5 to GPR75 due to CCR5 blockade) [effect is downreg CA2[+]
GRP78 (via M2 to M1 machrophage switch, via PI3K/AKT pathway downreg) [-]
Gsdmd [-]
inositol monophosphate (IP-1) IP-1 implicated in bi-polar disorder)), HbA1c (correlated with CCL5), HDL (high density lipoprotein) [+]
HGF, HIF-1a (via STAT3 downreg)[-]
HIF-2a (via NF-kb downreg)[-]
ICAM-1(intercellular adhesion molecule-)[-]
IDO (via IFN-y downreg) [-]
IFN-a (via downreg GM-CSF) [-]
IFNy (BACH2 upregulation)[-]
IL-1b (via caspase-1 downreg)[-]
IL-1Ra [+]
IL-2 [-]
IL-4 (-)
IL-5, IL-6 (via CCL5) [-]
IL-8 [-]
IL-10 [?]
IL-13 [-],
IL-16 [-]
IL-17a (via upregulation of CD69 and subsequent downregulation of TH17 cells)[-]
IL-18 (via caspase-1 downreg)[-]
IL-33, IL-36 (via TNF-a and ILF downreg)[-]
Jak 1, 2 and 3[-]
JNK (c-Jun N-terminal kinases) [-]
LDL (low density lipoprotein)[-]
LFA-1(lymphocyte function–associated antigen-1) [-]
macrophage polarization M2 to M1 shift, MapK (p38 MAPK)[-]
MDSC (via downreg CCL5) [-]
MEK [-]
miR21 (via downreg TFNa) [-]
MMP-1 [-]
MMP-2 (via CCL3 downreg)[-]
MMP-3, MMP-9 (CCL5/PLC pathway) [-]
MMP-12 [-]
MMP-13, mTORc1[-]
N-GSDMD [-]
NETosis[-]
neuropilin-1[-]
NF-H (neurofilament heavy) [+]
NF-kb (via PI3K/AKT downreg) [-]
NFAT (via CA2+ downreg) [-]
NLRP1 [-]
NLRP3 (via IL-36, ATP, ROS downreg) [-]
NOS (nitric oxide synthase) (via downreg NF-kb, MAPK) [-]
NO (nitric oxide) (via downreg NOS) [-]
Nox1 (via CCL5) [-]
p21 (tumor suppressor) (via downreg of PI3K/AKT)[+]
p27 (tumor suppressor) [+]
p38 [-]
p50 (via NF-kb downreg) [-]
p53 [-]
p55 (aka CD25) [-]
p-CREB [+]
PCNA [-]
PDK1 (via PI3K)[-]
PD-L1(via downreg Nf-kb/MapK/JAK2) [-]
PDGF-B (upreg from ADA2) [-]
PI3k (via blocking CCL4 activation) [-]
PKA-Ca [+]
PKB/AT (CCL3,CCL5 blockade)[-]
PKC [protein kinase C] [via CA2+ downreg][-]
PKR (via TNF-a downreg) -[-]
PLA2 (via CCL2, CCL3, CCL5, CCL7, TNF-a, IL-1b, IFNy, GM-CSF downreg) [-]
PLC (CCL5 blockade)[-],
PPARy [+]
Prostaglandin D2 (formed from arachidonic acid) [-]
Pyk2 (via RAFTK) [-]
RAFTK (downreg of bradykinin, CCL5) [-]
RAGE [-]
RAS (via downreg Src) [-]
Reg3a [-]
ROS (via CCL5)[-]
S100A4 (via downreg of CCL5) [-]
SCG3 (Secretogranin III)(via downreg CA2+)[-]
sFas (via Nf-kB)[-]
SHP1[-]
SHP2[-]
SOCS3 [-]
SORT1 (neurotensin receptor-3) (MAP and PI3K dependent) [-]
SRC (via downregulation of Pyk2) [-]
SREBP-1a [-]
SREBP-2 [-]
STAT3 [-]
STAT4 (feedback loop, also increases CCR5) [-]
STAT5 [-]
SYK (via CCL4) [-]
TGF-b [-]
TIMP-1 [-]
TIMP-2 [-]
TIMP-3 [-]
TNF-a (via IL-10, MEK downreg)[-]
TNFR2 [-]
TFN-y, TGF-b) [-]
TNFSF14, TRPM4 (via CA-2+ downreg) [-]
TSC2 (via AKT downreg) [+]
TSLP (thymic stromal lymphopoietin) (via IL-1b, IL-4, IL-13, TNF-a downreg)[-]
VCAM-1 (via TNF-a, IL-1 downreg) [-]
VEGF [-]
ZAP70 (via CCL5) [-]
[+] = upregulation
[-] = downregulation
a-SMA [-]
a1-antitrypsin [+]
ADA2 (CCL5 migration to site of injury) [-]
AKT (via blockade of CCL4)[-], AMPK [+]
arachidonic acid (upregulated by CCL2, CCL3, CCL4, CCL5, CCL7 [-]
CCL8)[-]
AP-1 [-]
ARG1 [-]
ASC proteins (via NLRP3 downreg)[-]
ATP (via CCL5 downreg) [-]
b-arrestin [-]
BACH2 (via decrease of inflammatory TREG reaponse) [+]
Bcl-2 [-]
BDNF [+]
bradykinin[-]
beta- catenin (via downreg CCL5/CCL2) [-]
bFGF (-)
BTK (via SYK) [-]
c-Raf (via downreg of b-arrestin) [-]
caspase-1 (via NLRP3/ASC downreg) [-]
capase-3 [-]
capase 9 [-]
C5a [-]
CA-2+[-]
Calcineurin (via downreg CA-2+[-]
cAMP (via CD38)[-]
CCL2 (MCP-1)[-]
CCL3 (MIP-1a)[-]
CCL4 (MIP-1b)[-]
CCL5 (RANTES)[-]
CCL7 (MCP-3)[-]
CCL8 (MCP-2)[-]
CCL11(Eotaxin-1)(low binding affinity) (high binding of CCR3)[-]
CCL13 (MCP-4)[-]
CCL14 (HCC-1)[-]
CCL16 (HCC-4)[-]
CCL18 [-]
CCL20 (LARC MIP3A)(not a CCR5 ligand) (via NF-kB downreg)[-]
CCR1 (via TNF-a and IL-4) [-]
CD25 (aka p55)(IL-2 receptor) [-]
CD69 [+]
CDK2 (via CCL5 downreg) [-]
CDK4 (via CCL5 downreg) [-]
CDK6 (via CCL5 downreg) [-]
CREB [+]
CTLA-4 (via IFN-a downreg)[-]
CX3CL1 (fractalkine) (NF-kB /TNF-a downregulation)[-]
CXCL1 [-]
CXCL8 [-]
CXCR4 (via downreg IL-17a, cyclin D1 (via CCL5 downreg) [-]
cyclin E (via CCL5 downreg) [-]
cytochrome c (via CCL5 downreg)[-]
DNMT1 (vis downreg of STAT3)[-]
ECM [-]
EGF/EGFR (in cancer via downreg fibroblasts, downreg GRP78) [-]
EGR-1 (via downreg of MAPK)[-]
eIF2a (via PKR downreg) [-]
eIF4E [-]
EN-RAGE [-]
Erk 1 and 2[-]
FAK (via CCL5) [-]
FLNa, FOXP3 (downregulation of PKB/Akt pathway)[+]
GLP-1 [+]
GLUT-1 (via CCL5 downreg) [-]
GM-CSF (CSF2)[-]
GPR75 (increased binding of CCL5 to GPR75 due to CCR5 blockade) [effect is downreg CA2[+]
GRP78 (via M2 to M1 machrophage switch, via PI3K/AKT pathway downreg) [-]
Gsdmd [-]
inositol monophosphate (IP-1) IP-1 implicated in bi-polar disorder)), HbA1c (correlated with CCL5), HDL (high density lipoprotein) [+]
HGF, HIF-1a (via STAT3 downreg)[-]
HIF-2a (via NF-kb downreg)[-]
ICAM-1(intercellular adhesion molecule-)[-]
IDO (via IFN-y downreg) [-]
IFN-a (via downreg GM-CSF) [-]
IFNy (BACH2 upregulation)[-]
IL-1b (via caspase-1 downreg)[-]
IL-1Ra [+]
IL-2 [-]
IL-4 (-)
IL-5, IL-6 (via CCL5) [-]
IL-8 [-]
IL-10 [?]
IL-13 [-],
IL-16 [-]
IL-17a (via upregulation of CD69 and subsequent downregulation of TH17 cells)[-]
IL-18 (via caspase-1 downreg)[-]
IL-33, IL-36 (via TNF-a and ILF downreg)[-]
Jak 1, 2 and 3[-]
JNK (c-Jun N-terminal kinases) [-]
LDL (low density lipoprotein)[-]
LFA-1(lymphocyte function–associated antigen-1) [-]
macrophage polarization M2 to M1 shift, MapK (p38 MAPK)[-]
MDSC (via downreg CCL5) [-]
MEK [-]
miR21 (via downreg TFNa) [-]
MMP-1 [-]
MMP-2 (via CCL3 downreg)[-]
MMP-3, MMP-9 (CCL5/PLC pathway) [-]
MMP-12 [-]
MMP-13, mTORc1[-]
N-GSDMD [-]
NETosis[-]
neuropilin-1[-]
NF-H (neurofilament heavy) [+]
NF-kb (via PI3K/AKT downreg) [-]
NFAT (via CA2+ downreg) [-]
NLRP1 [-]
NLRP3 (via IL-36, ATP, ROS downreg) [-]
NOS (nitric oxide synthase) (via downreg NF-kb, MAPK) [-]
NO (nitric oxide) (via downreg NOS) [-]
Nox1 (via CCL5) [-]
p21 (tumor suppressor) (via downreg of PI3K/AKT)[+]
p27 (tumor suppressor) [+]
p38 [-]
p50 (via NF-kb downreg) [-]
p53 [-]
p55 (aka CD25) [-]
p-CREB [+]
PCNA [-]
PDK1 (via PI3K)[-]
PD-L1(via downreg Nf-kb/MapK/JAK2) [-]
PDGF-B (upreg from ADA2) [-]
PI3k (via blocking CCL4 activation) [-]
PKA-Ca [+]
PKB/AT (CCL3,CCL5 blockade)[-]
PKC [protein kinase C] [via CA2+ downreg][-]
PKR (via TNF-a downreg) -[-]
PLA2 (via CCL2, CCL3, CCL5, CCL7, TNF-a, IL-1b, IFNy, GM-CSF downreg) [-]
PLC (CCL5 blockade)[-],
PPARy [+]
Prostaglandin D2 (formed from arachidonic acid) [-]
Pyk2 (via RAFTK) [-]
RAFTK (downreg of bradykinin, CCL5) [-]
RAGE [-]
RAS (via downreg Src) [-]
Reg3a [-]
ROS (via CCL5)[-]
S100A4 (via downreg of CCL5) [-]
SCG3 (Secretogranin III)(via downreg CA2+)[-]
sFas (via Nf-kB)[-]
SHP1[-]
SHP2[-]
SOCS3 [-]
SORT1 (neurotensin receptor-3) (MAP and PI3K dependent) [-]
SRC (via downregulation of Pyk2) [-]
SREBP-1a [-]
SREBP-2 [-]
STAT3 [-]
STAT4 (feedback loop, also increases CCR5) [-]
STAT5 [-]
SYK (via CCL4) [-]
TGF-b [-]
TIMP-1 [-]
TIMP-2 [-]
TIMP-3 [-]
TNF-a (via IL-10, MEK downreg)[-]
TNFR2 [-]
TFN-y, TGF-b) [-]
TNFSF14, TRPM4 (via CA-2+ downreg) [-]
TSC2 (via AKT downreg) [+]
TSLP (thymic stromal lymphopoietin) (via IL-1b, IL-4, IL-13, TNF-a downreg)[-]
VCAM-1 (via TNF-a, IL-1 downreg) [-]
VEGF [-]
ZAP70 (via CCL5) [-]
(12)
(0)
Scroll down for more posts â–Ľ